All News
Osteoarthritis related bio markers associated with MRI imaging biomarkers
⭐️COMP and MMP-3 negatively associated with knee cartilage thickness
⭐️serum biomarkers could predict future MRI based markers
Abs#POS0129
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
If a patient w/ PsA has high disease activity, would you take the rapid escalator approach (bDMARD) or a step-wise approach (csDMARD to start & escalate per response)?
Be sure to check out Dr. L Coates great talk on personalized tx approach! #EULAR2021 @RheumNow @ElaineHusniMD
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Can biologics change our gut microbiome?
TNFi in IBD related SpA study
⭐️⬇️proteobacteria, ⬆️lachnospiraceae
⭐️TNFi could restore intestinal eubiosis
Abs#POS0230
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Can we act on modifiable predictors of PsA?
⭐️Higher BMI associated with PsA progression from PsO
⭐️family history of PsA, nail pitting predicted PsA development
Abs#POS0145
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
How to Watch EULAR 2021 with Dr. Jack Cush
Listen to RheumNow editor Dr. Jack Cush talk about how to take in all the amazing EULAR 2021 content and information this week. #EULAR2021
https://t.co/cXwUO7J9YS https://t.co/JAieLdAnyb
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 – Day 2 Report
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Read our highlights.
https://t.co/NbBqPbbiUy https://t.co/1m6R9F7XWf
Links:
Dr. John Cush RheumNow ( View Tweet)
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Links:
Dr. John Cush RheumNow ( View Tweet)
HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up?
#OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy
Aurelie Najm AurelieRheumo ( View Tweet)
Just a reminder: RA-ILD doesn't just happen in early disease; risk continues on long after diagnosis.
PS don't smoke if you have RA; smokers have an adj HR 1.92
PPS don't smoke if you don't want to get RA
PPPS don't smoke.
@MayoClinic POS0210 #EULAR2021 @RheumNow https://t.co/elhvJrK7B4
David Liew drdavidliew ( View Tweet)
Presenting now at #EULAR2021
#COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with #rituximab: a cohort study
https://t.co/QTGkiMcC2d https://t.co/DJB6GooPuJ
Links:
The Lancet Rheumatology TheLancetRheum ( View Tweet)
#EULAR2021. OP0293: Best disease activity measure for SLE flares?
⭐️c-SFI and SLE-DAS had best performance
⭐️SLE-DAS: easy to use for daily practice
@RheumNow https://t.co/9LJfbYxqOs
Eric Dein ejdein1 ( View Tweet)
Which RA pts have high HAQ? F/U of 2 ERA cohorts [NOAR 1001 pts, #ESPOIR 767 pts] compared pts with high vs lower HAQ. DAS28 was = in 2 groups! But high HAQ occurred in older, females &⬆️fatigue OP0183 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope ( View Tweet)
Sounds fishy! Krill oil in #osteoarthritis is not a good catch! Fully neg RCT POS0276 @eular_org @RheumNow #EULAR2021 https://t.co/OGZbltDyxg
Janet Pope Janetbirdope ( View Tweet)
How many of your postmenopausal RA ♀️ patients are on osteoporotic treatment?
#EULAR2021 POS0164
⭐️28% had prior fragility FX
⭐️50.5% at very high or high risk of fx according to FRAX 10 yr major fx risk
Over 1/2 of patients at risk & indicated for treatment!
@RheumNow
Eric Dein ejdein1 ( View Tweet)
Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
2021 GRAPPA STRONG recs (cont'd):
*⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
🚫strong rec against IL17i
2021 GRAPPA CONDITIONAL recs for:
*⃣ Uveitis: TNFi (not ETN), CyA
*⃣ Crohn's Dz & UC: IL23i, JAKi, MTX
OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence of RA-BR of 18.7% (some may have been subclinical). POS0522 Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis #EULAR2021 @Janetbirdope
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope Janetbirdope ( View Tweet)
2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
